



#5 Receipt

PATENT
Customer No. 22,852
Attorney Docket No. 2356.0076-01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
)
Pierre CHARNEAU et al.) Group Art Unit: Not assigned
)
Application No.: 10/026,741) Examiner: Not assigned
)
Filed: December 27, 2001)
)
For: NUCLEOTIDE SEQUENCES OF)
HIV-1 TYPE (OR SUBTYPE) O)
RETROVIRUS ANTIGENS)
COMMISSIONER FOR PATENTS) OFFICE OF INITIAL PATENT EXAMINATION
Washington, DC 20231

Sir:

REQUEST FOR CORRECTED FILING RECEIPT

We are forwarding herewith a copy of a Filing Receipt for the above-identified patent application. The error is found in the title. The title should read:

**--NUCLEOTIDE SEQUENCES OF HIV-1 TYPE (OR SUBTYPE) O
RETROVIRUS ANTIGENS--**


The correct title is shown in ink on the attached copy of the Filing Receipt.


It is respectfully requested that a corrected Filing Receipt be issued as soon as possible.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: March 8, 2002

By: 
Kenneth J. Meyers
Reg. No. 25,146



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO.	DRAWINGS	TOT CLAIMS	IND CLAIMS
10/026,741	12/27/2001	1648	740	2356.0076-01	37	8	3

CONFIRMATION NO. 2062

22852

FINNEGAN, HENDERSON, FARABOW, GARRETT &
DUNNER LLP
1300 I STREET, NW
WASHINGTON, DC 20005

RECEIVED

FILING RECEIPT

OC00000007523196

FEB 28 2002

FINNEGAN, HENDERSON,
FARABOW, GARRETT & DUNNER, LLP.

Date Mailed: 02/25/2002

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. **If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).**

Applicant(s)

Pierre Charneau, Paris, FRANCE;
Francois Clavel, Paris, FRANCE;
Andrew Borman, Villemeux-Sur-Eure, FRANCE;
Caroline Quillent, Vitry-Sur-Seine, FRANCE;
Denise Guetard, Paris, FRANCE;
Luc Montagnier, Le Plessis-Robinson, FRANCE;
Jacqueline Donjon De Saint-Martin, Clamart, FRANCE;
Jacques H.M. Cohen, Reims, FRANCE;

Assignment For Published Patent Application

Institut Pasteur;

Domestic Priority data as claimed by applicant

THIS APPLICATION IS A CON OF 08/817,441 07/11/1997
WHICH IS A 371 OF PCT/FR95/01391 10/20/1995

Foreign Applications

FRANCE 94/12554 10/20/1994
FRANCE 95/02526 03/03/1995

If Required, Foreign Filing License Granted 02/22/2002

Projected Publication Date: 06/06/2002

Docketed 2/28/02 Attorney KJM/SJA
Case 2356-76
Due Date 8/6/02
Action CORR OR REVISION OF CLAIMS
By KQ

Non-Publication Request: No

Early Publication Request: No

Title

Nucleotide sequences of HIV-1 group (or subgroup) O retroviral antigens

Preliminary Class

435

↑
TYPE subtype

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).